Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
14.46 M
About MediGene AG
Sector
Industry
Website
Headquarters
Martinsried
Founded
1996
ISIN
DE000A40ESG2
FIGI
BBG000DZHK95
MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. It focuses on the development of personalized T-cell based immunotherapies. It operates through the Immunotherapies and Other products segments. The company was founded by Ernst Ludwig Winnacker and Horst Domdey in June 1994 and is headquartered in Martinsried, Germany.
Related stocks
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange MediGene AG stocks are traded under the ticker MDG1.
MDG1 reached its all-time high on Feb 21, 2018 with the price of 36.5740 EUR, and its all-time low was 0.0482 EUR and was reached on Aug 5, 2025. View more price dynamics on MDG1 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
Yes, you can track MediGene AG financials in yearly and quarterly reports right on TradingView.
MediGene AG is going to release the next earnings report on Mar 26, 2026. Keep track of upcoming events with our Earnings Calendar.
No, MDG1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, MDG1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MediGene AG stock right from TradingView charts — choose your broker and connect to your account.